Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19398929 | 0.69 | PDPK1 (0.46) | MEN1KMT2AHDAC6POLBHPGD | |
| SCHEMBL722976 | 0.69 | HPGD (0.41) | MEN1KMT2AHDAC6POLBHPGD | |
| SCHEMBL11207511 | 0.68 | HPGD (0.44) | MEN1KMT2AHDAC6POLBHPGD | |
| SCHEMBL24630095 | 0.67 | ALDH1A1 (0.44) | MEN1KMT2AHDAC6POLBHPGD | |
| SCHEMBL23023688 | 0.67 | GRM5 (0.44) | MEN1KMT2AHDAC6POLBALDH1A1 | |
| SCHEMBL621953 | 0.67 | SMN1; SMN2 (0.49) | MEN1KMT2AHDAC6POLBHPGD | |
| SCHEMBL569774 | 0.65 | — | — | |
| SCHEMBL875204 | 0.65 | POLB (0.43) | MEN1KMT2AHDAC6POLBHPGD | |
| SCHEMBL3007288 | 0.64 | PDPK1 (0.44) | MEN1KMT2AHDAC6POLBHPGD | |
| SCHEMBL8847636 | 0.64 | HPGD (0.39) | MEN1KMT2AHDAC6POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287703-A1 | Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | claimed |
| EP-1773830-A1 | FUSED PYRIMIDONES USEFUL IN THE TREATMENT AND THE PREVENTION OF CANCER | AstraZeneca AB (SE) | 2007-04-18 | — | — | EP | claimed |
| WO-2006008523-A1 | FUSED PYRIMIDONES USEFUEL IN THE TREATMENT AND THE PREVENTION OF CANCER | ASTRAZENECA AB (SE) | 2006-01-26 | — | — | WO | claimed |
| US-20090171082-A1 | MITOTIC KINESIN INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-7504405-B2 | Mitotic kinesin inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080249112-A1 | Mitotic Kinesin Inhibitors | CHIRON CORPORATION (US) | 2008-10-09 | — | — | US | disclosed |
| US-20070287703-A1 | Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| EP-1773830-A1 | FUSED PYRIMIDONES USEFUL IN THE TREATMENT AND THE PREVENTION OF CANCER | AstraZeneca AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| EP-1732926-A1 | MITOTIC KINESIN INHIBITORS | CHIRON CORPORATION (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006008523-A1 | FUSED PYRIMIDONES USEFUEL IN THE TREATMENT AND THE PREVENTION OF CANCER | ASTRAZENECA AB (SE) | 2006-01-26 | — | — | WO | disclosed |
| WO-2005100357-A1 | MITOTIC KINESIN INHIBITORS | CHIRON CORPORATION (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050228002-A1 | Mitotic kinesin inhibitors | CHIRON CORPORATION (US) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171082-A1 | MITOTIC KINESIN INHIBITORS | KIF5B, KIF2C, KIFC1 | MEN1 1508/4885KMT2A 477/4885HDAC6 116/4885 |
| US-20070287703-A1 | Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer | DHFR, DPYD, TYMP | MEN1 1265/4885KMT2A 3856/4885HDAC6 2120/4885 |
| US-20050228002-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIFC1 | MEN1 1508/4885KMT2A 477/4885HDAC6 116/4885 |
| US-20080249112-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIFC1 | MEN1 1408/4885KMT2A 473/4885HDAC6 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.